

# Diabetic Neuropathy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/D1CA3AB1810EN.html>

Date: May 2020

Pages: 135

Price: US\$ 2,000.00 (Single User License)

ID: D1CA3AB1810EN

## Abstracts

Diabetic Neuropathy - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy – Pipeline Review, H1 2020, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

'Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet, pain or discomfort in the feet or legs – including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.'

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features

dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 12, 8, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Diabetic Neuropathy - Overview

Diabetic Neuropathy - Therapeutics Development

Diabetic Neuropathy - Therapeutics Assessment

Diabetic Neuropathy - Companies Involved in Therapeutics Development

Diabetic Neuropathy - Drug Profiles

Diabetic Neuropathy - Dormant Projects

Diabetic Neuropathy - Discontinued Products

Diabetic Neuropathy - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Diabetic Neuropathy, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2020  
Diabetic Neuropathy - Pipeline by Angelini Group, H1 2020  
Diabetic Neuropathy - Pipeline by Applied Therapeutics Inc, H1 2020  
Diabetic Neuropathy - Pipeline by Arena Pharmaceuticals Inc, H1 2020  
Diabetic Neuropathy - Dormant Projects, H1 2020  
Diabetic Neuropathy - Dormant Projects, H1 2020 (Contd..1), H1 2020  
Diabetic Neuropathy - Dormant Projects, H1 2020 (Contd..2), H1 2020  
Diabetic Neuropathy - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Diabetic Neuropathy, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Achelios Therapeutics Inc  
Angelini Group  
Applied Therapeutics Inc  
Arena Pharmaceuticals Inc  
Bionevia Pharmaceuticals  
Bol Pharma  
Bristol-Myers Squibb Co  
Calchan Ltd  
Celularity Inc  
Commence Bio Inc  
CSPC Pharmaceutical Group Ltd  
Exodos Life Sciences Limited Partnership  
Glycadia Inc  
GNT Pharma Co Ltd  
Grifols SA  
Grunenthal GmbH  
Immune Pharmaceuticals Inc  
Ion Channel Pharmacology LLC  
Jiangsu Aosaikang Pharmaceutical Co Ltd  
Kineta Inc  
Medifron DBT Co Ltd  
Mitsubishi Tanabe Pharma Corp

Omeros Corp  
Pfizer Inc  
Praetego Inc  
Reata Pharmaceuticals Inc  
Seneca Biopharma Inc  
Sichuan Haisco Pharmaceutical Co Ltd  
Sonnet BioTherapeutics Holdings Inc  
Sphaera Pharma Pte Ltd  
WEX Pharmaceuticals Inc  
Winsantor Inc  
YD Life Science Co  
Zhejiang Pharmaceutical Co Ltd



## I would like to order

Product name: Diabetic Neuropathy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/D1CA3AB1810EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D1CA3AB1810EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970